文献速递前列腺癌

膳食和循环番茄红素水平升高与前列腺癌风险降低相关:系统综述与荟萃分析

Increased dietary and circulating lycopene are associated with reduced prostate cancer risk: a systematic review and meta-analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2017-04-25

该系统综述与剂量反应荟萃分析纳入42项研究、692012名参与者中43851例前列腺癌病例,发现膳食番茄红素摄入(RR=0.88,95%CI:0.78-0.98,P=0.017)和循环番茄红素浓度(RR=0.88,95%CI:0.79-0.98,P=0.019)均与前列腺癌风险降低显著相关,且存在剂量反应关系;但番茄红素与晚期前列腺癌无关联。

要点

  • 膳食番茄红素摄入与前列腺癌风险降低显著相关(RR=0.88,95%CI:0.78-0.98,P=0.017)。
  • 循环番茄红素浓度与前列腺癌风险降低显著相关(RR=0.88,95%CI:0.79-0.98,P=0.019)。
  • 每增加2 mg膳食番茄红素摄入,前列腺癌风险降低1%(P=0.026);循环番茄红素每增加10 μgdl-1,风险降低3.5%至3.6%。

核心结论

  • 较高的膳食和循环番茄红素浓度与前列腺癌风险呈负相关,并伴随剂量反应关系;但番茄红素与晚期前列腺癌风险降低无关。
  • 需要进一步研究来确定这些关联背后的机制。

研究设计与样本

  • 系统综述与剂量反应荟萃分析,纳入2016年12月1日前发表于PubMed、Web of Science和Cochrane Library的合格研究。
  • 共纳入42项研究,包含692012名参与者中报告的43851例前列腺癌病例。
  • 采用随机效应模型和固定效应模型估计合并相对危险度(RR)及95%置信区间(CI),并评估线性和非线性剂量反应关系。

主要发现

  • 膳食番茄红素摄入与前列腺癌风险降低显著相关(RR=0.88,95%CI:0.78-0.98,P=0.017)。
  • 循环番茄红素浓度与前列腺癌风险降低显著相关(RR=0.88,95%CI:0.79-0.98,P=0.019)。
  • 剂量反应分析中,膳食番茄红素每额外摄入2 mg,前列腺癌风险降低1%(P=0.026)。
  • 线性和非线性模型中,循环番茄红素每额外增加10 μgdl-1,前列腺癌风险分别降低3.5%和3.6%(plinear=0.004,pnonlinear=0.006)。
  • 番茄红素与晚期前列腺癌无关联,但对前列腺癌侵袭性有保护趋势(RR=0.74,95%CI:0.55-1.00,P=0.052)。

局限性

  • 需要进一步研究来确定这些关联背后的机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate cancer (PCa) is the fifth leading cause of cancer-related deaths worldwide. Many epidemiological studies have investigated the association between prostate cancer and lycopene, however, results have been inconsistent. This study aims to determine the impact of dietary and circulating concentrations of lycopene on PCa risk and to investigate potential dose-response associations. METHODS: We conducted a systematic review and dose-response meta-analysis for the for the association between dietary and circulating lycopene and PCa risk. Eligible studies were published before 1 December 2016 and were identified from PubMed, Web of Science and the Cochrane Library. We estimated pooled relative risk ratios (RR) and 95% confidence intervals (CI) using random and fixed effects models. Linear and nonlinear dose-response relationships were also evaluated for PCa risk. RESULTS: Forty-two studies were included in the analysis, which included 43 851 cases of PCa reported from 692 012 participants. Both dietary intake (RR=0.88, 95% CI: 0.78-0.98, P=0.017) and circulating concentrations (RR=0.88, 95% CI: 0.79-0.98, P=0.019) of lycopene were significantly associated with reduced PCa risk. Sensitivity analyses within the dose-response analysis further revealed a significant linear dose-response for dietary lycopene and PCa risk such that PCa decreased by 1% for every additional 2 mg of lycopene consumed (P=0.026). Additionally, PCa risk decreased by 3.5 to 3.6% for each additional 10 μgdl-1 of circulating lycopene in the linear and nonlinear models respectively (plinear=0.004, pnonlinear=0.006). While there were no associations between lycopene and advanced PCa, there was a trend for protection against PCa aggressiveness (RR=0.74, 95% CI: 0.55-1.00, P=0.052). CONCLUSIONS: Our data demonstrate that higher dietary and circulating lycopene concentrations are inversely associated with PCa risk. This was accompanied by dose-response relationships for dietary and circulating lycopene. However, lycopene was not associated with a reduced risk of advanced PCa. Further studies are required to determine the mechanisms underlying these associations.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Rowles JL, Ranard KM, Smith JW, et al. Increased dietary and circulating lycopene are associated with reduced prostate cancer risk: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2017. PMID: 28440323. doi:10.1038/pcan.2017.25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。